These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 54800)

  • 1. Clofibrate-induced muscle damage in patients with chronic renal failure.
    Pierides AM; Alvarez-Ude F; Kerr DN
    Lancet; 1975 Dec; 2(7948):1279-82. PubMed ID: 54800
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factorial study of the efficacy of cholestyramine, L-tryptophan and clofibrate in human nephrotic hyperlipidaemia.
    Schapel GJ; Edwards KD; Neale FC
    Prog Biochem Pharmacol; 1974; 9():82-98. PubMed ID: 4438384
    [No Abstract]   [Full Text] [Related]  

  • 3. Clofibrate-induced myopathy in patients with diabetes insipidus.
    Matsukura S; Matsumoto J; Chihara K; Yoshimoto Y; Fujita T
    Endocrinol Jpn; 1980 Jun; 27(3):401-3. PubMed ID: 7439122
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clofibrate-induced myopathy in a patient with primary hypothyroidism.
    Hattori N; Shimatsu A; Murabe H; Nishimura M; Nakamura H; Imura H
    Jpn J Med; 1990; 29(5):545-7. PubMed ID: 2089182
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clofibrate, serum enzymes, and muscle pain.
    Smith AF; Macfie WG; Oliver MF
    Br Med J; 1970 Apr; 2(5701):86-8. PubMed ID: 5420239
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Treatment of primary hyperlipoproteinaemia types, IIa, IIb, 3 and IV with clofibrate (author's transl)].
    von Löwis P; Klemens UH
    Dtsch Med Wochenschr; 1973 Dec; 98(49):2328-33. PubMed ID: 4357927
    [No Abstract]   [Full Text] [Related]  

  • 7. One-year trials with halofenate, clofibrate, and placebo.
    Dujovne CA; Azarnoff DL; Huffman DH; Pentikäinen P; Hurwitz A; Shoeman DW
    Clin Pharmacol Ther; 1976 Mar; 19(3):352-9. PubMed ID: 177242
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clofibrate-induced acute muscular syndrome.
    Sekowski I; Samuel P
    Am J Cardiol; 1972 Oct; 30(5):572-4. PubMed ID: 5073673
    [No Abstract]   [Full Text] [Related]  

  • 9. Clinical and metabolic effects of pentaerythritol tetranicotinate in combination with cholesolvin or clofibrate.
    Olsson AG; Orö L; Rössner S
    Atherosclerosis; 1974; 19(3):407-15. PubMed ID: 4364073
    [No Abstract]   [Full Text] [Related]  

  • 10. Clinical trial of methyl clofenapate (a derivative of clofibrate) in patients with essential hyperlipidaemias--with special reference to type II (primary) hyperlipidaemia.
    Craig GM; Walton KW
    Atherosclerosis; 1972; 15(2):189-98. PubMed ID: 4579956
    [No Abstract]   [Full Text] [Related]  

  • 11. Control of clofibrate toxicity in uremic hypertriglyceridemia.
    Goldberg AP; Sherrard DJ; Haas LB; Brunzell JD
    Clin Pharmacol Ther; 1977 Mar; 21(3):317-25. PubMed ID: 837651
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical importance of clofibrate induced increase of creatine kinase catalytic activity concentration in serum.
    Schneider J
    J Clin Chem Clin Biochem; 1981 Aug; 19(8):539-40. PubMed ID: 7276838
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clofibrate treatment of hyperlipidemia in chronic renal failure.
    di Giulio S; Boulu R; Drüeke T; Nicolaĭ A; Zingraff J; Crosnier J
    Clin Nephrol; 1977 Dec; 8(6):504-9. PubMed ID: 598055
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of Preclinical Liver and Skeletal Muscle Biomarkers Following Clofibrate Administration in Wistar Rats.
    Maliver P; Festag M; Bennecke M; Christen F; Bánfai B; Lenz B; Winter M
    Toxicol Pathol; 2017 Jun; 45(4):506-525. PubMed ID: 28485676
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Changes in serum aspartate and alanine aminotransferase, lactate dehydrogenase, gamma-glutamyltransferase and creatine kinase activities and the myoglobin level during hemodialysis].
    Starzyk J; Kowalski D
    Wiad Lek; 1988 Oct; 41(20):1357-60. PubMed ID: 2907702
    [No Abstract]   [Full Text] [Related]  

  • 16. Acute muscular syndrome associated with administration of clofibrate.
    Langer T; Levy RI
    N Engl J Med; 1968 Oct; 279(16):856-8. PubMed ID: 5677720
    [No Abstract]   [Full Text] [Related]  

  • 17. [Low dose clofibrate in the treatment of hypertriglyceridemia in hemodialysis patients (author's transl)].
    Jarillo MD; Coca MC; Díaz Rubio C; Bello I; Gutiérrez-Millet V; Ruilope LM; Rodicio JL; Alvarez Ude F
    Med Clin (Barc); 1980 Nov; 75(8):334-7. PubMed ID: 7442334
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Hypolipemic property and myotoxic action of clofibrate in a case of nephrotic syndrome].
    Fabre J; Denizot M; Wildi E; Micheli H; Berthoud S
    Schweiz Rundsch Med Prax; 1973 Jun; 62(23):732-7. PubMed ID: 4705828
    [No Abstract]   [Full Text] [Related]  

  • 19. Fenofibrate increases creatininemia by increasing metabolic production of creatinine.
    Hottelart C; El Esper N; Rose F; Achard JM; Fournier A
    Nephron; 2002; 92(3):536-41. PubMed ID: 12372935
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protective effects of clofibrate on isoproterenol-induced myocardial infarction in arteriosclerotic and non-arteriosclerotic rats.
    Wexler BC; Greenberg BP
    Atherosclerosis; 1978 Mar; 29(3):373-95. PubMed ID: 666886
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.